HUMDF (Hua Medicine) EPS (Basic): $0.16 (TTM As of Dec. 2025)


HUMDF Hua Medicine HUMDF
46 GF Score
Price $0.34
GF Value $1.46
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Hua Medicine EPS (Basic)?

Hua Medicine HUMDF 46 EPS (Basic) is $0.16 as of Dec. 2025. GuruFocus rates HUMDF with a GF Score™ of 46/100 and a GF Value™ of $1.46 (Possible Value Trap). The stock has 6 warning signs investors should review.

Hua Medicine's basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was $-0.01. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.16.

Hua Medicine's EPS (Diluted) for the six months ended in Dec. 2025 was $-0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.15.

Hua Medicine's EPS without NRI for the six months ended in Dec. 2025 was $-0.01. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -0.02.

During the past 3 years, the average EPS without NRI Growth Rate was 13.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was 18.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 10 years, Hua Medicine's highest 3-Year average EPS without NRI Growth Rate was 66.90% per year. The lowest was -16.40% per year. And the median was 13.70% per year.

Hua Medicine  (OTCPK:HUMDF) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Hua Medicine EPS (Basic) Related Terms

Hua Medicine EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Hua Medicine's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hua Medicine EPS (Basic) Chart

Hua Medicine Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.05 -0.03 -0.03 -0.03 0.16

Hua Medicine Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.02 -0.01 0.17 -0.01
HUMDF
46GF Score
Hua Medicine HUMDF
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hua Medicine EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Hua Medicine's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(157.081-0)/987.815
=0.16

Hua Medicine's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-11.017-0)/990.722
=-0.01

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $0.16 mean?
Hua Medicine (HUMDF) has a EPS (Basic) of $0.16 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Hua Medicine and its competitors.
Is Hua Medicine's EPS (Basic) too high?
Hua Medicine's current EPS (Basic) is $0.16. Overall, Hua Medicine has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hua Medicine's EPS (Basic) compare to ZTS and UTHR?
Hua Medicine's EPS (Basic) of $0.16 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Hua Medicine and its competitors. Hua Medicine's current EPS (Basic) is $0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hua Medicine stock overvalued right now?
Based on GuruFocus' analysis, Hua Medicine (HUMDF) is currently considered Possible Value Trap. The stock's GF Value™ is $1.46, compared to a current price of $0.34 — trading 76.7% below its estimated fair value. The current EPS (Basic) is $0.16. Hua Medicine's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Hua Medicine (HUMDF), the current EPS (Basic) is $0.16 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hua Medicine (HUMDF) Overvalued in 2026?

Based on GuruFocus' analysis, Hua Medicine stock appears to be undervalued. The current stock price of $0.34 is trading 76.7% below its estimated GF Value™ of $1.46. GuruFocus considers Hua Medicine to be Possible Value Trap.

Key valuation signals for HUMDF:

  • EPS (Basic): $0.16
  • GF Value™: $1.46 vs. price of $0.34 (76.7% below fair value)
  • GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the HUMDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hua Medicine Business Description

Other Exchanges 02552:Hong Kong
Address Lane 36, Xuelin Road, Hua Medicine, Building 2, Pudong New Area, Shanghai, CHN, 201203
Hua Medicine is an investment holding company. It is engaged in the development and commercialization of a first-in-class oral drug, Dorzagliatin (HMS5552), for the treatment of Type 2 diabetes. Dorzagliatin is a first-in-class glucokinase activator, or GKA, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in Type 2 diabetes. The group majorly operates and generates the majority of its revenue from the PRC.
46GF Score

Get the complete analysis for HUMDF

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.34
Price
$1.46
GF Value